In CTGF-mediated diseases, letrozole could relieve the process of liver fibrosis by inhibiting the YAP-CTGF pathway to reduce the level of CTGF and suppress the retinoic acid in the hepatocytes [116,117]. This evidence concerns the gene CCN2 and Hepatic fibrosis.